Full-Time

Director – Franchise Lead Supply Chain

Multiple Teams

Posted on 9/6/2025

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

No salary listed

Dublin, Ireland

Remote

Candidates must be based in Ireland.

Category
Operations & Logistics (2)
,
Required Skills
Inventory Management
SAP Products
Requirements
  • Strong understanding and experience in GMP pharmaceutical supply chain management
  • Strong knowledge and experience of using ERP systems such as SAP
  • Knowledge of product serialization implementation and operations
  • High level of customer orientation/understanding
  • Attention to detail and accuracy
  • Ability to influence internal and external constituents
  • Strong interpersonal and communication skills. Able to prepare and deliver reports to Senior Management
  • Accountable to meet goals and objectives
  • Strong project management and organizational skills
  • Strong people skills and supportive of Jazz values
Responsibilities
  • Report to the Senior Director Global Supply Chain Network Planning
  • Responsible for overseeing and managing the end to end supply chain for a Franchise portfolio of Jazz products
  • Role covers all aspects of planning, procurement, distribution in compliance with applicable GxP and other regulations
  • Hands-on experience in end-to-end supply chain management, including demand planning, production scheduling, and inventory management on qualified ERP systems eg SAP
  • Responsible for Commercial brand supply continuity
  • Responsible for the accurate execution of Procurement/planning activities on SAP
  • Translate the product supply strategy through to tactical execution
  • Develop supply scenarios and responses to local/global events
  • Responsible for Commercial brand scorecard and performance metrics
  • Agree strategy and Manage inventory across the manufacturing and supply network
  • Ensure compliance across all aspects of SC scope – regulatory, quality, finance, trade etc
  • Lead the Franchise planning team to execute the tactical plans based on agreed strategy
  • Responsible for planning and supply of raw materials, intermediates, components and finished goods for portfolio of Jazz products
  • Supports the Tech Ops relationship management for key supply chain vendors
  • Lead the implementation of Supply Chain systems and processes to manage the supply of all products including controlled drug product for patients
  • Lead the planning and scheduling of product with partners, ensuring timely supply of compliant product to patients and achieving supply chain business objectives as required
  • Manage performance, relationships and improvements with supply chain manufacturing and distribution partners through regular, structured communication processes including face to face meetings as required
  • Develop and implement metrics to monitor and record, using appropriate systems, usage of critical raw materials, API/drug substance and finished products and ensuring accuracy of information to assist with supply chain decision making
  • Manage the relationship with commercial partners and other functions to understand and obtain demand forecasts
  • Develop and lead the S&OP, MRP and other supply management processes implementation to ensure patient supply
  • Responsible for supply chain compliance with GxP, trade, financial and other regulations to ensure continued patient supply
  • Identify, contribute to and lead projects with other functions (such as Tech Ops, QA, RA, Finance etc) as required to achieve supply chain objectives
  • Lead other Supply Chain projects as identified and required
  • Demonstrate Jazz management competencies (technical, planning, communication, interpersonal, leading, judgment skills)

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Xywav and Epidiolex continue driving double-digit neuroscience revenue growth.
  • Zepzelca's first-line SCLC uptake expands Jazz's oncology franchise rapidly.
  • Chimerix adds dordaviprone, strengthening the late-stage rare-brain-cancer pipeline.

What critics are saying

  • Oxybate franchise concentration exposes revenue to payer pressure and competitive switching.
  • Epidiolex growth slows if adult and long-term-care adoption disappoints.
  • Oncology upside depends on continued Zepzelca and zanidatamab execution.

What makes Jazz Pharmaceuticals unique

  • Rare-disease focus spans neuroscience and oncology with limited-treatment options.
  • Jazz built growth through acquisitions like GW Pharmaceuticals, Celator, and Chimerix.
  • Dublin incorporation and global footprint support cross-border operations and tax optimization.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Jazz Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.

INACTIVE